CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
BI 1265162 (T1) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03907280
NCT03907280Phase 1Completed
CompareCT.gov

Absolute Bioavailability of BI 1265162 Following Oral and Inhaled Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study Followed by a Fixed Treatment)

Boehringer Ingelheim·interventional·Posted Apr 8, 2019·Updated Jul 6, 2022

In Brief

A Phase 1 clinical trial evaluating BI 1265162 (T1), BI 1265162 (T2), and 2 other interventions for Healthy. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The main objective of this trial is to investigate the absolute bioavailability of BI 1265162 following administration of oral solution and inhaled (with and without charcoal) via Respimat.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 8, 2019
Enrollment StartApr 23, 2019
Primary CompletionDec 6, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.2 years ago

Interventions

BI 1265162 (T1)drug

oral solution

BI 1265162 (T2)drug

Solution for inhalation

BI 1265162 (R)drug

concentrate for i.v. solution

BI 1265162 (T3)drug

Solution for inhalation